GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.

dc.contributor.authorRico, Mikel
dc.contributor.authorFlamarique, Sonia
dc.contributor.authorCasares, Cristina
dc.contributor.authorGarcía, Tamara
dc.contributor.authorLópez, Miriam
dc.contributor.authorMartínez, Maribel
dc.contributor.authorSerrano, Javier
dc.contributor.authorBlanco, Manuel
dc.contributor.authorHernanz, Raúl
dc.contributor.authorde Ingunza-Barón, Lourdes
dc.contributor.authorMarcos, Francisco José
dc.contributor.authorCouñago, Felipe
dc.date.accessioned2025-01-07T12:49:49Z
dc.date.available2025-01-07T12:49:49Z
dc.date.issued2021
dc.description.abstractThymic epithelial tumours (TET) are rare, heterogeneous neoplasms that range from resectable indolent tumours to aggressive thymic carcinomas with a strong tendency to metastasize. The pathological diagnosis is complex, in part due to the existence of several different classification systems. The evidence base for the management of TETs is scant and mainly based on non-randomised studies and retrospective series. Consequently, the clinical management of TETs tends to be highly heterogenous, which makes it difficult to improve the evidence level. The role of technological advances in the field of radiotherapy and new systemic therapies in the treatment of TETs has received little attention to date. In the present clinical guidelines, developed by the GOECP/SEOR, we review recent developments in the diagnosis and classification of TETs. We also present a consensus-based therapeutic strategy for each disease stage that takes into consideration the best available evidence. These guidelines focus primarily on the role of radiotherapy, including recent advances, in the management of TETs. The main aim of this document is to promote the standardisation of clinical practice and lay the foundations for future studies to clarify the main unresolved questions related to the optimal management of TET.
dc.identifier.doi10.5306/wjco.v12.i4.195
dc.identifier.issn2218-4333
dc.identifier.pmcPMC8085511
dc.identifier.pmid33959475
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8085511/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.5306/wjco.v12.i4.195
dc.identifier.urihttps://hdl.handle.net/10668/24970
dc.issue.number4
dc.journal.titleWorld journal of clinical oncology
dc.journal.titleabbreviationWorld J Clin Oncol
dc.language.isoen
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.organizationSAS - Hospital Universitario Puerta del Mar
dc.page.number195-216
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectChemotherapy
dc.subjectGuidelines
dc.subjectRadiotherapy
dc.subjectReirradiation
dc.subjectTargeted therapies
dc.subjectThymic epithelial tumors
dc.titleGOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8085511.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format